Design and synthesis of novel enhanced water soluble hydroxyethyl analogs of combretastatin A-4

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 7, 2011, Pages 2087-2091

  Lee, Megan ^a   Brockway, Olivia ^a   Dandavati, Armaan ^a   Tzou, Samuel ^a   Sjoholm, Robert ^a   Nickols, Alexis ^a   Babu, Balaji ^a   Chavda, Sameer ^a   Satam, Vijay ^a   Hartley, Rachel M ^b   Westbrook, Cara ^b   Mooberry, Susan L ^b   Fraley, Gregory ^a   Lee, Moses ^a  

^a HOPE COLLEGE   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Combretastatins; Cytotoxicity; Lymphoma; Melanoma; Microtubules; Solubility; Tubulin

Indexed keywords

1 (1' HYDROXYETHYL) 1 (3'',4'',5'' TRIMETHOXYPHENYL) 2 (SUBSTITUTED PHENYL)ETHENE; 2 CYCLOHEXENONE; 2 THIOXOPYRIMIDINE; A 105972; AC 7739; ACETYL COMBRETASTIN DERIVATIVE; COMBRETASTATIN A4; OXADIAZOLINE DERIVATIVE; PYRAZOLE; TETRAZOLIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DEPOLYMERIZATION; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GEOMETRY; IC 50; LYMPHATIC LEUKEMIA; LYMPHOMA; MELANOMA; MOLECULAR MODEL; MOUSE; NONHUMAN; X RAY CRYSTALLOGRAPHY;

ANIMALS; CELL LINE, TUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; SOLUBILITY; STILBENES; WATER;

MURINAE;

EID: 79952485257     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.136     Document Type: Article

References (31)

1. Pettit, G. R.; Singh, S. B.; Niven, M. L.; Hamel, E.; Schmidt, J. M. J. Nat. Prod. 1987, 50, 119;
2. Dorr, R. T.; Dvorakova, K.; Snead, K.; Alberts, D. S.; Salmon, S. E.; Pettit, G. R. Invest. New Drugs 1996, 14, 131.
3. Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.; Schmidt, J. M.; Pettit, G. R.; Hamel, E. Mol. Pharmacol. 1988, 34, 200.
4. Chaplin, D. J.; Pettit, G. R.; Hill, S. A. Anticancer Res. 1999, 19, 189.
5. Pettit, G. R.; Toki, B. E.; Herald, D. L.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Chapuis, J.-C. J. Med. Chem. 1999, 42, 1459;
6. Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Chaplin, D. J.; Stratford, M. R. L.; Hamel, E.; Pettit, R. K.; Chapuis, J.-C.; Oliva, D. Anti-Cancer Drug Des. 1998, 13, 981.
7. Chaplin, D. J.; Pettit, G. R.; Parkins, C. S.; Hill, S. A. Br. J. Cancer 1996, 27, 586.
8. Wu-Wong, J. R.; Alder, J. D.; Alder, L.; Burns, D. J.; Han, E. K.-H.; Credo, B.; Tahir, S. K.; Dayton, B. D.; Ewing, P. J.; Chiou, W. J. Cancer Res. 2001, 61, 1486;
9. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Experientia 1989, 45, 209;
10. Nam, N. H. Current Med. Chem. 2003, 10, 1697;
11. Pati, H. N.; Mishra, B. K.; Babu, B.; Hiriyanna, S. G. Biomed. 2009, 4, 1;
12. Chaudhary, A.; Pandeya, S. N.; Kumar, P.; Sharma, P. P.; Gupta, S.; Soni, N.; Verma, K. K. Mini-Reviews Med. Chem. 2007, 7, 1186;
13. Holt, H., Jr; Lee, M.; Brown, T. Top. Heterocyl. Chem. 2006, 2, 1;
14. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. J. Med. Chem. 2006, 49, 3033.
15. LeBlanc, R.; Dickson, J.; Brown, T.; Stewart, M.; Pati, H. N.; VanDerveer, D.; Arman, H.; Harris, J.; Pennington, W.; Holt, H.; Lee, M. Bioorg. Med. Chem. 2005, 13, 6025.
16. Johnson, M.; Younglove, B.; Lee, L.; LeBlanc, R.; Holt, H.; Patrice, H.; Mackay, H.; Brown, T.; Mooberry, S. L.; Lee, M. Bioorg. Med. Chem. Lett. 2007, 17, 5897.
17. Ruprich, J.; Prout, A.; Dickson, J.; Younglove, B.; Nolan, L.; Baxi, K.; LeBlanc, R.; Forrest, L.; Hills, P.; Holt, H., Jr.; Mackay, H.; Brown, T.; Mooberry, S. L.; Lee, M. Lett. Drug Des. Discovery 2007, 4, 144.
18. Lee, L.; Lyda, M. R.; Lee, M.; Davis, R.; Mackay, H.; Chavda, S.; Babu, B.; O'Brien, A. L.; Risinger, E. L.; Mooberry, S. L.; Lee, M. J. Med. Chem. 2010, 53, 325.
19. Lee, L.; Davis, R.; Vanderham, J.; Hills, P.; Mackay, H.; Brown, T.; Mooberry, S. L.; Lee, M. Eur. J. Med. Chem. 2008, 43, 2011.
20. Chavda, S.; Davis, R.; Ferguson, A.; Riddering, C.; Dittenhafer, K.; Mackay, H.; Babu, B.; Lee, M.; Siegfried, A.; Pennington, W.; Shadfan, M.; Mooberry, S. L.; Mishra, B. K.; Pati Hari, N. Lett. Drug Des. Discovery 2009, 7, 531;
21. Babu, B.; Lee, M.; Lee, L.; Strobel, R.; Brockway, O.; Nickols, A.; Sjoholm, R.; Chavda, S.; Desta, D.; Fraley, G.; Pennington, W.; Mooberry, S. L.; Kiakos, K.; Hartley, J. A.; Lee, M. Bioorg. Med. Chem. 2010, accepted for publication.
22. Ducki, S.; Forrest, R.; Hadfield, J. H.; Kendall, A.; Lawrence, N. J.; McGown, A. T.; Rennison, D. Bioorg. Med. Chem. Lett. 1998, 8, 1051.
23. Takeya, T.; Okubo, T.; Nishida, S.; Tobinaga, S. Chem. Pharm. Bull. 1985, 33, 3599.
24. Kupchinsky, S.; Centioni, S.; Howard, T.; Trzupek, J.; Roller, S.; Carnahan, V.; Townes, H.; Purnell, B.; Price, C.; Handl, H.; Summerville, K.; Johnson, K.; Toth, J.; Hudson, S.; Kiakos, K.; Hartley, J. A.; Lee, M. Bioorg. Med. Chem. 2004, 12, 6221.
25. Boyd, R. B. The NCI In Vitro Anticancer Drug Discovery Screen In Teicher, B., Ed.; Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval; Humana Press Inc.: Totowa, NJ, 1997; pp 23-42.
26. Cox, C.; Breslin, M.; Mariano, B.; Coleman, P.; Buser, C.; Walsh, E.; Hamilton, K.; Huber, H.; Kohl, N.; Torrent, M.; Yan, Y.; Kuo, L.; Hartman, G. Bioorg. Med. Chem Lett. 2005, 15, 2041;
27. (b) Fraley, M.; Garbaccio, R. M.; Arrington, K. L.; Hoffman, W. F.; Tasber, E. S.; Coleman, P. J.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Fernandes, C.; Schaber, M. D.; Lobell, R. B.; Tao, W.; South, V. J.; Yan, Y.; Kuo, L.; Prueksaritanont, T.; Shu, C.; Torrent, M.; Heimbrook, D. C.; Kohl, N. E.; Huber, H. E.; Hartman, G. D. Bioorg. Med. Chem. Lett. 2006, 16, 1775;
28. Garbaccio, R. M.; Fraley, M. E.; Tasber, E. S.; Olson, C. M.; Hoffman, W. F.; Arrington, K. L.; Torrent, M.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Schaber, M. D.; Fernandes, C.; Lobell, R. B.; Tao, W.; South, V. J.; Yan, Y.; Kuo, L. C.; Prueksaritanont, T.; Slaughter, D. E.; Shu, C.; Heimbrook, D. C.; Kohl, N. E.; Huber, H. E.; Hartman, G. D. Bioorg. Med. Chem. Lett. 2006, 16, 1780.
29. Gupton, J. T.; Burham, B. S.; Krumpe, K.; Du, K.; Sikorski, J. A.; Warren, A. E.; Barnes, C. R.; Hall, I. H. Arch. Pharm. 2000, 333, 3.
30. Sato, A.; McNulty, L.; Cox, K.; Kim, S.; Scott, A.; Daniell, K.; Summerville, K.; Price, C.; Hudson, S.; Kiakos, K.; Hartley, J. A.; Asao, T.; Lee, M. J. Med. Chem. 2005, 48, 3903.
31. The stock drug solutions were prepared by first dissolving 45 mg of each compound in a total of 450 μL of absolute ethanol, 900 μL of polyethylene glycol 400 and 150 μL Tween 80. Each solution was then diluted to a final volume of 3000 μL with a solution consisting of 1200 μL 5% glucose in sterile water and 300 μL of DMSO to give stock solutions for each compound comprising of a 75 mg/kg dosage. Both solutions were prepared in glass vials and stored at room temperature. Each 100 μL injection delivers 1.5 mg of the drug into the mice via an ip route.